MedicarePartD.guide

A non-government resource built from CMS public data

Long-acting (basal) insulin on BlueCross Rx Value (S5953-001)

Lantus, Basaglar, Tresiba and the other basal insulins, checked against this plan's 2026 formulary (its list of covered drugs).

Plan type
Stand-alone drug plan (PDP), South Carolina
Premium
$139.70/month
Deductible
$615.00, doesn't apply to tier 1 and 6
Change plan

3 of 7 Long-acting insulin are covered on this plan. None require prior authorization.

4 aren't on the formulary, including insulin glargine and Basaglar.

  • Lantus
    insulin glargine
    Covered
    17%
    Tier 3
  • Toujeo
    insulin glargine, U-300
    Covered
    17%
    Tier 3
  • Tresiba
    insulin degludec
    Covered
    17%
    Tier 3
Not on the formulary
insulin glargine, Basaglar, Semglee, Rezvoglar

Patient cost for a 30-day supply at a preferred retail pharmacy, after the $615.00 deductible where it applies. Where the plan charges a percentage (coinsurance), the dollar figure is that share of the plan's negotiated price; "from" means other strengths cost more. Data from the CMS 2026 Part D formulary and pricing files.

Full plan details · This plan's whole drug list